Evolving Paradigm of PARP-Inhibitors and Combination Therapies for mCRPC

Thursday, November 16, 2023, 8:00 AM - Friday, November 15, 2024, 11:59 PM

AMA PRA Category 1 Credits™ (1.25 hours), AMA PRA Category 1 Credits™ Designated (1.25 hours)


There is an unmet need to develop newer therapies beyond targeting AR signaling for mCRPC. PARP inhibitors are targeted agents that treat HRR-deficient tumors. Olaparib, rucaparib, niraparib, veliparib, and talazoparib were evaluated in phase trials as monotherapy and with combinations for mCRPC. The combination approach has shown impressive early efficacy signals in clinical settings and appears poised for a breakthrough.

There are no fees to participate in the activity. Participants must review all activity contents, including the learning objectives, disclosure statements, and post activity assessment to receive CME credit for participation.

Contact Information

Brian Waggoner, Program Manager
MedNet, LLC
[email protected]

1. Summarize the mechanism of action of the PARP inhibitors, mutations in the DNA damage response (DDR) pathway, and predictive biomarkers;
2. Appraise the therapeutic potential of novel PARP-inhibitor combinations in the treatment of patients with HRR-deficient mCRPC.

PHYSICIAN CREDIT (ACCME)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Medical Media Holdings, Inc. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSE PRACTIONERS CREDIT
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.25 hours.

PHYSICIAN ASSISTANT/ASSOCIATES CREDIT
PAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)^TM from organizations accredited by ACCME or a recognized state medical society.

COI / Disclosure of Relationships with Ineligible Entities

In accordance with the ACCME Standards for Integrity and Independence Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24-months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education, or whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant relationships have been mitigated. The University of Cincinnati, Medical Media Holdings, and the peer/content reviewers for this activity have no relevant conflict of interest to report.

Medical Director & Program Planners

Medical Media Holding Inc.
Kamatham A. Naidu, PhD
Brian Waggoner

University of Cincinnati, Center for Continuous Professional Development (CME)
Susan P. Tyler, PhD, Associate Dean
Heather Muskopf, Program Director
Bruce C. Gebhardt, MD, Peer Reviewer

Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Disclaimer Statement
The opinions expressed during this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati and MedNet, LLC. The information is presented for the purpose of advancing the attendees’ professional development.

COI / Disclosure of Relationships with Ineligible Entities

In accordance with the ACCME Standards for Integrity and Independence Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24-months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education, or whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant relationships have been mitigated. The following disclosures were made:

Wassim Abida, MD, PhD
Director of Translational Research
Prostate Cancer, Associate Member, Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Abida discloses that he is a consultant: Clovis Oncology, Daiichi Sankyo, Janssen, AstraZeneca, ORIC Pharmaceuticals; speaker: Aptitude Health, Medscape, Roche, Clinical Education Alliance; received travel grants: Clovis Oncology, GlaxoSmithKline, ORIC Pharmaceuticals; received research funding (to my institution): AstraZeneca, Clovis Oncology, Epizyme, GlaxoSmithKline, Zenith Epigenetics, Nuvation, Merus

Benjamin A. Teply, MD
Associate Professor of Medicine Division of Hematology/Oncology
Fred & Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, NE

Dr. Teply discloses that he is on the advisory board: Seagen, Sanofi, Lilly, Exelixis; and grant reviewer: Pfizer/Myovant

Mitigation of Relevant Financial Relationships

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant relationships have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

 

This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen.